Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
暂无分享,去创建一个
J. Raemaekers | A. Hagenbeek | G. Salles | F. Berger | J. Baars | E. Noordijk | J. Bosq | E. W. Van Den Neste | U. Tirelli | P. Lugtenburg | O. Reman | M. Henry-Amar | P. Lederlin | J. Gabarre | J. Walewski | P. Brice | G. Creemers | P. Poortmans | C. Carrie | E. Gyan | H. Eghbali | P. Carde | J. Kluin-Nelemans | T. Girinsky | M. V. van't Veer | José Thomas | J. Jaubert | M. Blanc | M. Diviné | B. Vié | J. Meerwaldt | C. Fermé | C. Rieux | M. Monconduit | F. Viseu | E. Van Den Neste | J. Thomas | M. Diviné
[1] M. Gordon. Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin’s Lymphoma: Final Results of the GHSG HD7 Trial , 2008 .
[2] E. Baraldi,et al. Chronic lung disease after premature birth. , 2007, The New England journal of medicine.
[3] J. Raemaekers,et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Connors,et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Yahalom,et al. Transformation in the use of radiation therapy of Hodgkin lymphoma: New concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT) , 2005, European journal of haematology. Supplementum.
[6] J. Raemaekers,et al. The EORTC strategy in the treatment of Hodgkin's lymphoma , 2005, European journal of haematology. Supplementum.
[7] A. Zelenetz,et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. , 2004, Blood.
[8] R. Greil,et al. Reduction of Combined Modality Treatment Intensity in Early Stage Hodgkin’s Lymphoma: Interim Analysis of the HD 10 Trial of the GHSG. , 2004 .
[9] M. Alfò,et al. Intermediate stage Hodgkin's disease: preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy. , 2004, Anticancer research.
[10] G. Bonadonna,et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] K. Naresh,et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Dirk Hasenclever,et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] P. Davis,et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Friedberg,et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. , 2002, Blood.
[15] R. Fisher,et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] A. Husain,et al. Pathology of arrested acinar development in postsurfactant bronchopulmonary dysplasia. , 1998, Human pathology.
[17] M Tubiana,et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J. Connors,et al. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program. , 1988, Seminars in hematology.
[19] K. Rothman,et al. Epidemiologic Analysis with a Programmable Calculator , 1982 .
[20] C. Bloomfield,et al. Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy , 1980, Cancer.
[21] J. Herson,et al. Predictive probability early termination plans for phase II clinical trials. , 1979, Biometrics.